“Crowd sourcing drug development”. Can it really lead to drug repositioning?

After the NCATS pilot program ‘Discovering New Therapeutic Uses for Existing Molecules' was launched in May, a lot has been discussed about its potential and the actual feasibility to reposition one or some of the 58 compounds contributed by the eight big pharma joining the project. Experts in the field of drug repurposing say that there's very little opportunity for …

Top topics and companies in #Antibody Bispecific and Alternative Scaffold development

  In our recent European Antibody Congress survey we asked which topics are most important in terms of the further development and advancement antibody bispecifics and alternative scaffolds. The most important points that were identified and that you want to learn more about are; Optimizing biophysical properties of bispecific mAbs Bispecific in clinical trials Challenges in Developing Multivalent Antibodies: Preclinical …

Top topics and companies in antibody structure-function relationships

In our recent European Antibody congress Annual Survey we asked what the most important topics are for better understanding the mAb structure and function relationship. Below are the topics which came out on top; Therapeutic antibodies: Market considerations, disease targets and bioprocessing Engineering antibody structures Antibody structure optimization (OptimAbs) Improving antibody developability: How to Select the Optimal Biotherapeutic Antibody Candidate …